Susan Samson, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1790899227
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,560 of the $23,876 with a category attached, or 77.7%. Novo Nordisk accounts for 62.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $20,846 and has fallen 93.1% since, to $1,446 in 2025.
Across 39 payments — averaging $612.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$15K
- Corcept Therapeutics$5K
- Novartis$3K
- Chiesi USA, Inc.$1K
- Pfizer$131
- Xeris Pharmaceuticals, Inc.$43
- plus $28 from 2 others
Across 11 payments — averaging $1490.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- OPKO Pharmaceuticals, LLC$12K
- Novartis$3K
- Corcept Therapeutics$1K
What the payments were for
- Consulting fees$18,56078%
- Travel & lodging$3,83116%
- Food & beverage$1,4686%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $14,840 |
| Corcept Therapeutics | 15 | $4,556 |
| Novartis | 1 | $3,150 |
| Chiesi USA, Inc. | 7 | $1,128 |
| Pfizer | 2 | $131 |
| Xeris Pharmaceuticals, Inc. | 1 | $43 |
| Shire North American Group Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$14,280
- Korlym$4,114
- SIGNIFOR$3,150
- MYCAPSSA$999
How this compares
$23,876 in reported general payments places this provider in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IsturisaOsilodrostat Phosphate | 12 | $256,795 |
| Norditropin FlexproSomatropin | 14 | $47,083 |
| Testosterone | 28 | $6,145 |
| Cabergoline | 30 | $2,140 |
| Hydrocortisone | 50 | $1,952 |
| Testosterone Cypionate | 28 | $654 |
| Levothyroxine Sodium | 52 | $377 |
| Liothyronine Sodium | 11 | $314 |
| Prednisone | 16 | $181 |
| Dexamethasone | 14 | $29 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Wasim DeebJacksonville$286K
- Khurram WadudJacksonville$77K
- Senan SultanJacksonville$55K
- Firas WardaJacksonville$38K
- Maria Hurtado AndradeJacksonville$36K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.